Inasal (Salbutamol Sulfate, Ipratropium Bromide)

Salbutamol activates β2‑adrenergic receptors on airway smooth muscle, causing relaxation and widening of the airways. Ipratropium blocks muscarinic M3 receptors, preventing acetylcholine‑mediated bronchoconstriction. Together they produce a synergistic bronchodilatory effect that improves airflow.

The prescribed dose of Inasal is determined by the treating clinician based on the patient’s age, severity of disease, and response to therapy. Healthcare professionals select the appropriate number of inhalations and frequency according to clinical guidelines.

Safety data for Inasal in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Inasal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Inasal combines a short‑acting β2‑agonist (salbutamol) with an anticholinergic (ipratropium), offering a broader mechanism of action than single‑agent bronchodilators. This dual approach can provide faster symptom relief and better control of bronchospasm compared with agents that act on only one pathway.

Inasal should be stored at room temperature, below 25 °C, in its original packaging. Protect the container from moisture, direct sunlight, and extreme temperatures to maintain product stability.

Inasal is delivered via inhalation using a nebuliser or metered‑dose inhaler, as directed by a healthcare professional. The patient inhales the aerosolized solution into the lungs, ensuring the device is cleaned and maintained according to the manufacturer’s instructions.

Serious risks include paradoxical bronchospasm, angioedema, severe tachycardia or arrhythmias, and anaphylactic reactions. Patients should seek immediate medical attention if they experience sudden worsening of breathing, swelling of the face or throat, or rapid, irregular heartbeats.

Inasal should be avoided in individuals with known hypersensitivity to salbutamol, ipratropium, or any excipients in the formulation. Caution is also advised for patients with severe cardiac disease, uncontrolled hypertension, or narrow‑angle glaucoma, and it should only be used under medical supervision.